Emerging therapies in metastatic bone pain

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 441-458

  Coluzzi, Flaminia ^a,b   Mandatori, Ilenia ^a,b   Mattia, Consalvo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ICOT Unit of Anesthesia Intensive Care and Pain Medicine   (Italy)

Author keywords

bone metastases; cancer; cathepsin K; CXCR4; pain; RANKL; skeletal related events; Src; targeted therapy; Wnt

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 4 [3 (TRIFLUOROMETHYL) 2 PYRIDINYL] N [5 (TRIFLUOROMETHYL) 2 PYRIDINYL] 1 PIPERAZINECARBOXAMIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ALENDRONIC ACID; AMGN 0007; ANALGESIC AGENT; ARRY 470; ATRASENTAN; BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CATHEPSIN K; CHEMOKINE RECEPTOR CXCR4; CLODRONIC ACID; CORTICOSTEROID; DASATINIB; DENOSUMAB; DEXAMETHASONE; ENDOTHELIN A RECEPTOR; GABAPENTIN; IBANDRONIC ACID; KX 2391; NERVE GROWTH FACTOR; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SARACATINIB; SCLEROSTIN; SOTATERCEPT; TANEZUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; WAY 262611; WNT PROTEIN; ZIBOTENTAN; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; BONE METASTASIS; BONE PAIN; CANCER PAIN; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; EYE DISEASE; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MUSCULOSKELETAL PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT;

ANIMALS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959932437     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.576668     Document Type: Review

References (150)

1. Caraceni A, Portenoy PK. A working group of the IAPS task force on cancer pain: An international survey of cancer pain characteristics and syndromes. Pain 1999;16:263-74
2. Houston SJ, Rubens RD. The systemic treatment of bone metastases. Clin Orthop Relat Res 1995;312:539-42
3. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007;19:308-14
4. Goldberg G, Morrison R. Pain management in hospitalized cancer patients: A systematic review. J Clin Oncol 2007;25:1792-801
5. Yau V, Chow E, Davis L, et al. Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 2004;27:1-3
6. Mattia C, Ciarcia S, Muhindo A, et al. Nimesulide: 25 years later. Minerva Med 2010;101:285-93
7. Mattia C, Coluzzi F. COX-2 inhibitors: Pharmacological data and adverse effects. Minerva Anestesiol 2005;71:461-70
8. Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 2008;102:10-14
9. Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes 2009;117:38-43
10. Kalff KM, El Mouedden M, van Egmond J, et al. Pre-treatment with capsaicin in a rat osteoarthritis model reduces the symptoms of pain and bone damage induced by monosodium iodoacetate. Eur J Pharmacol 2010;641:108-13
11. Major PP, Lipton A, Berenson J, et al. Oral biphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000;88:6-14
12. Rose NAA, Siegel PM. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 2010;6:55-74 This review is a milestone for understanding the mechanisms underlying the newer proposed therapeutic targets in bone metastatic breast cancer.
13. Sabino MA, Ghilardi JR, Jongen JL, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor grwth by selective inhibition of cyclooxygenase-2. Cancer Res 2002;62:7343-9
14. Salari P, Abdollahi M. Controversial effects of non-steroidal anti-inflammatory drugs on bone: A review. Inflamm Allergy Drug Targets 2009;8:169-75
15. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006;31:242-7
16. Mattia C, Coluzzi F, Sarzi Puttini P, et al. Paracetamol/Tramadol association: The easy solution for mild-moderate pain. Minerva Med 2008;99:369-90
17. Mercadante S, Radbruch L, Caraceni A, et al. Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9
18. Darwish M, Kirby M, Robertson P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-50
19. Muller-Schwefe G, Jaksch W, Morlion B, et al. Make a CHANGE: Optimising communication and pain management decisions. Curr Med Res Opin 2011;27:481-8
20. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48:689-723
21. Buckeridge D, Huang A, Hanley J, et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc 2010;58:1664-70
22. Perez-Castrillon JL, Olmos JM, Gomez JJ, et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 2000;72:187-94
23. Rosen H, Krichevsky A, Bar-Shavit Z. The enkephalinergic osteoblast. J Bone Miner Res 1998;13:1515-20
24. Dy SM, Asch SM, Maeim A, et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008;26:3879-85
25. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann NY Acad Sci 2008;1138:278-98
26. Colvin L, Fallon M. Challenges in cancer pain management-bone pain. Eur J Cancer 2008;44:1083-90
27. Mattia C, Coluzzi F. Antidepressants in chronic neuropathic pain. Mini Rev Med Chem 2003;3:773-84
28. Wiffen PJ, Collins S, McQuay HJ, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2010;20:CD001133
29. Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: A randomized open trial. J Pain Symptom Manage 2007;34:183-9
30. Coleman RE. Should biphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol 2001;28(4 Suppl 11):35-41
31. Machado M, Cruz LS, Tannus G, et al. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials. Clin Ther 2009;31:962-79
32. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010;37(Suppl 2):S15-29
33. Gralow J, Tripathy D. Managing metastatic bone pain: The role of biphosphonates. J Pain Symptom Manage 2007;33:462-72
34. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001;88:701-7
35. Ernst DS, Brasher P, Hagen N, et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-26
36. Piga A, Bracci R, Ferretti B, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998;17:213-17
37. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14:2552-9
38. Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: A randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-92
39. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo- controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84
40. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Danish-Swedish Co-operative Study Group. Br J Haematol 1998;101:280-6
41. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
42. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
43. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-9
44. Heras P, Kritikos K, Hatzopoulos A, et al. Efficacy of ibadronate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care 2009;18:653-6
45. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of biphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62
46. Tsavaris N, Kopterides P, Kosmas C, et al. Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases. Oncol Rep 2006;16:871-5
47. Martinez-Zapata MJ, Roque M, Alonso-Coello P, et al. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2006;19:CD003223
48. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
49. Available from: Http://apps.nccd.cdc.gov [Accessed January 2011]
50. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-42
51. Allen JM. Economic/societal burden of metastatic breast cancer: A US perspective. Am J Manag Care 2010;16:697-704
52. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
53. Russell RG, Espina B, Hulley P. Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 2006;18(Suppl 1):S3-10
54. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116:1202-9
55. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25
56. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989;8:98-101
57. Guise T. Examining the metastatic niche: Targeting the microenvironment. Semin Oncol 2010;37(Suppl 2):S2-14 This is a comprehensive review of the physiology of bone remodeling and molecular mechanisms involved in bone metastases.
58. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005;15:57-62
59. Sterling JA, Edwards JR, Martin TJ, et al. Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. Bone 2011;48:6-15
60. Psaila B, Lyden D. The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 2009;9:285-93
61. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. Bone cancer pain. Ann NY Acad Sci 2010;1198:173-81 In this paper, there is a clear explanation of possible pathogenetic mechanisms at the basis of pain from bone metastases.
62. Halvorson KG, Sevcik MA, Ghilardi JR, et al. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 2006;22:587-600
63. Bogado CE, Zanchetta MB, Boailchuk JA, et al. Denosumab: What's New? Curr Osteoporos Rep 2011;9:12-19
64. Rachner TD, Benad P, Rauner M, et al. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009;108:106-16
65. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008;34:92-101
66. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-47
67. Wilson SR, Peters C, Saftig P, et al. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 2009;284:2584-92
68. Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009;24:744-52
69. Aleshin A, Finn RS. SRC: A century of science brought to the clinic. Neoplasia 2010;12:599-607
70. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-41
71. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005;65:9426-35
72. Hans G, Deseure K, Adriaensen H. Endothelin-1-induced pain and hyperalgesia: A review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides 2008;42:119-32
73. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(3 Suppl):887-92
74. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004;86:269-79
75. Lamoureux F, Moriceau G, Picarda G, et al. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta 2010;1805:17-24
76. Reddy GK, Mughal TI, Roodman GD. Novel approaches in the management of myeloma-related skeletal complications. Support Cancer Ther 2006;4:15-18
77. Pierroz DD, Bonnet N, Baldock PA, et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010;285:28164-73
78. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-57
79. Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
80. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009;14:1-34
81. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
82. Fizazi K, Sternberg CN, Fitzpatrick JM, et al. Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010;105:748-67
83. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011. [Epub ahead of print]
84. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zolendronic acid for the treatment of bone metastases in patients with breast cancer: A randomized, double-blind study. 2010;28:5132-9 This is the first randomized trial that compared clinical efficacy and safety of Denosumab and ZA.
85. Stoch SA, Zajic S, Stone J, et al. Effect of the Cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: Two double-blind, randomized, placebo-controlled Phase I studies. Clin Pharmacol Ther 2009;86:175-82
86. Jensen AB, Wynne C, Ramirez G, et al. The Cathepsin K inhibitor odanacatib suppresses one resorption in women with breast cancer and established bone metastases: Results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010;10:452-8
87. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00747123
88. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT01074138
89. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00410813, NCT00566618, NCT00936975
90. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00558272, NCT01144481
91. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00545129; NCT00830180
92. Carducci MA, Saad F, Abrahamsson PA, et al. Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66
93. Nelson JB, Love W, Chin JL, et al. Atrasentan Phase 3 Study Group. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478-87
94. Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270-6
95. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00134056
96. Warren R, Liu G. ZD4054: A specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 2008;17:1237-45
97. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-5
98. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55:1112-23
99. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010;106:966-73
100. Schelman WR, Liu G, Wilding G, et al. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 2011;29:118-25
101. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00617669
102. Chouaid C, Nathan F, Pemberton K, et al. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010. [Epub ahead of print]
103. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT01205711; NCT01134497; NCT00929162
104. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005;102:13909-14
105. Available from: Http://clinicaltrials.gov. [Accessed January 2011]. NCT00844064; NCT00761280; NCT00431561
106. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009;155:231-6
107. Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009;21:761-7
108. Hassan S, Buchanan M, Jahan K, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2010. [Epub ahead of print]
109. Greinix HT, Worel N. New agents for mobilizing peripheral blood stem cells. Transfus Apheresis Sci 2009;41:67-71
110. Choi HY, Yong CS, Yoo BK. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother 2010;44:117-26
111. Kessans MR, Gatesman ML, Kockler DR. Plerixafor: A peripheral blood stem cell mobilize. Pharmacotherapy 2010;30:485-92
112. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 1997;389:816-24 This historic paper is a milestone in understanding the role of capsaicin receptors in pain pathway.
113. Ghilardi JR, Rohrich H, Lindsay TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005;25:3126-31
114. Niiyama Y, Kawamata T, Yamamoto J, et al. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth 2009;102:251-8
115. Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 2009;78:211-16
116. Honore P, Chandran P, Hernandez G, et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009;142:27-35
117. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: Targeting a pivotal point in the pain pathway. Drug Discov Today 2009;14:56-67
118. Klionsky L, Tamir R, Holzinger B, et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J Pharmacol Exp Ther 2006;319:192-8
119. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. Mol Pain 2010;6:87
120. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Sustained blockade of neurotrophin receptor TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone 2011;48:389-98
121. Curto-Reyes V, Llames S, Hidalgo A, et al. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 2010;160:561-73
122. Lozano-Ondoua AN, Wright C, Vardanyan A, et al. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci 2010;86:646-53
123. Choi SJ, Kurihara N, Oba Y, et al. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J Bone Miner Res 2001;16:1804-11
124. Thomas DM. Wnts, bone and cancer. J Pathol 2010;220:1-4
125. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810
126. Spencer GJ, Utting JC, Etheridge SL, et al. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006;119:1283-96
127. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324-9
128. Grisanti M, Nju QT, Fan W, et al. Dkk-1 inhibition increases bone mineral density in rodents. J Bone Miner Res 2006;21:S25
129. Bodine PVN, Stauffer B, Ponce-de- Leon H, et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 2009;44:1063-8
130. Pelletier JC, Lundquist JT IV, Gilbert AM, et al. (1-(4-(Naphthalen-2- yl)pyrimidin-2-yl)piperidin-4 yl) methanamine: A wingless beta-catenin agonist that increases bone formation rate. J Med Chem 2009;52:6962-5
131. Liu J, Wu X, Mitchell B, et al. A small-molecule agonist of the Wnt signaling pathway. Angew Chem Int Ed 2005;44:1987-90
132. Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 2005;102:17406-111
133. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24
134. Hall CL, Kang S, MacDougald OA, et al. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006;97:661-72
135. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554-60
136. Bu G, Lu W, Liu CC, et al. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int J Cancer 2008;123:1034-42
137. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94
138. Gavriatopoulou M, Dimopoulos MA, Christoulas D, et al. Dickkopf-1: A suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009;13:839-48
139. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-11
140. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371-9
141. Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009;24:425-36
142. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89
143. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005;90:6392-5
144. van Bezooijen RL, ten Dijke PPapapoulos SE, et al. SOST/ sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319-27
145. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-9
146. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-88
147. Padhi D, Jang G, Stouch B, et al. Singledose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26
148. Available from: Http://clinicaltrials.gov. [Accessed March 2011]. NCT00896532
149. Available from: Http://clinicaltrials.gov [Accessed March 2011]. NCT01081678; NCT00907296
150. Derry S, Lloyd R, Moore RA, et al. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009;4:CD007393